Question 1

What is Nxera Pharma?

Accepted Answer

Nxera Pharma is a Company.

Question 2

How often does Nxera Pharma appear in global news?

Accepted Answer

Tracked across 7 news events drawn from 45 articles.

Question 3

When was Nxera Pharma first tracked by Ergen?

Accepted Answer

First tracked on Apr 20, 2026.

Question 4

When was Nxera Pharma last mentioned in news?

Accepted Answer

Last active on Aug 07, 2026.

Question 5

What is Nxera Pharma's current news sentiment?

Accepted Answer

Aggregate sentiment score: 29 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Nxera Pharma in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 7 events.

Question 7

What is the most recent event involving Nxera Pharma?

Accepted Answer

Nxera Pharma joins OpenFold consortium (Jun 10, 2026, 9 articles).

Question 8

Who is Nxera Pharma most connected to?

Accepted Answer

Top relationships: Santhera Pharmaceuticals (licensee, investor), Santhera Pharmaceuticals (licensor, investee).

Question 9

How did the "Nxera Pharma joins OpenFold consortium" event impact Nxera Pharma?

Accepted Answer

Nxera Pharma joined the OpenFold consortium to enhance its AI-enabled drug discovery capabilities, particularly for GPCR targets, aligning with its strategy to improve R&D productivity and achieve its 2030 vision. This move is expected to strengthen its competitive position in the biopharmaceutical market.

Question 10

How did the "Nxera Pharma Q2 2026 Results" event impact Nxera Pharma?

Accepted Answer

Nxera reported strong Q2 results with revenue growth and profitability, driven by milestone payments and progress across its pipeline. The company's strategic partnerships and licensing deals position it for continued growth.

Question 11

How did the "AGAMREE receives South Korea designations" event impact Nxera Pharma?

Accepted Answer

Nxera Pharma holds exclusive rights to AGAMREE in Japan, South Korea, Australia, and New Zealand, and plans to submit a Marketing Authorization Application in South Korea during 2026. This designation will accelerate the review process for AGAMREE.

Question 12

How did the "AGAMREE Phase 1 Study Results" event impact Nxera Pharma?

Accepted Answer

Nxera Pharma holds commercialization rights for AGAMREE in Japan, South Korea, Australia, and New Zealand. Positive clinical data could support future market expansion in its licensed territories.

Question 13

How did the "Santhera expands Biomedica distribution deal" event impact Nxera Pharma?

Accepted Answer

Nxera Pharma holds rights for Japan, South Korea, Australia, and New Zealand; not impacted by this expansion.

Question 14

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.